Associated Papers
PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.
Lahera A et al.
Npj Precision Oncology, 2024
39033228 (PubMed )
Supplement: 41698_2024_638_MOESM1_ESM.pdf
Select a paper to view details